Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

Patients were randomized to abbreviated eptifibatide infusion (<2 hours) (n = 312) versus standard 18-hour infusion (n = 312). At enrollment, the use of aspirin was 100%, adequate clopidogrel ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 ...

14 days Manufacturer Eptifibatide 2 mg/mL Integrilin (Schering) 60 days Prescribing information Erythromycin ethylsuccinate oral suspension EES (Abbott) 14 days Prescribing information Etanercept ...

Frozen vials of Pfizer's Covid-19 vaccine may be stored at temperatures commonly found in pharmaceutical freezers for a period of up to two weeks, the US Food and Drug Administration said on Thursday.

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...

Diluted EPS in a Range of $2.80 to $3.00 The fourth-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday ...